mBeach Software Inc. (“MBHS”) (MBHS 0.26, +0.03, +13.04%) , in accordance with company policy which recognizes the importance of regular communication and timely information delivered to investors, is committed to sharing with our stockholders regular updates on progress.
We have reached our first, post merger milestone and have assessed our goal achievements for the past four months.
mBeach’s goals for the first milestone included redefining the activities of mBeach and Skin Cancer Scanning Ltd., instigating initial international marketing activities, progressing in the development of SkinScan 650, and strengthening and increasing shareholder value.
Redefining the core competence activities — SCS is now focused on its core competencies of research and development, regulatory issues, and conducting further clinical trials in Israel. MBHS is focused on worldwide business and marketing activities. This restructuring will maximize companies’ synergies.
Marketing activities — mBeach has recently signed an MOU with a Russian company for initiating marketing activities in Russia and the Commonwealth of Independent States (CIS). We have identified the Japanese, Hi-Tech orientated market as a potential pivotal market, with increasing awareness to skin cancer related issues. We are now operating to initiate marketing steps into this market.
The U.S. market has been, since inception, the major target market and all development has been conducted in light of DFA and Reimbursement programs’ requirements.
We expect these combined activities will increase and create stronger, long term, shareholder value.
Source:http://www.marketwatch.com/story/mbeach-software-inc-focusing-on-end-results-and-goal-achievements-of-first-post-merger-milestone-2010-09-29?reflink=MW_news_stmp
